Potential use of lurasidone for the treatment of bipolar psychosis

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 575-584

  Carta, Mauro Giovanni ^a   Moro, Maria Francesca ^a   Nardi, Antonio E ^b   Calabrese, Joseph R ^c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorders; Lurasidone; Psychotic simptoms; Second generation antipsychotics; Stabilizers

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM; LURASIDONE; SEROTONIN 7 RECEPTOR; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADD ON THERAPY; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; COGNITION; CONSCIOUSNESS DISORDER; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMITTER RELEASE; NONHUMAN; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; WEIGHT GAIN; ANIMAL; PATHOPHYSIOLOGY; PSYCHOTIC DISORDERS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; ISOINDOLES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES;

EID: 84924814547     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1009976     Document Type: Review

References (69)

1. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
2. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, doubleblind, placebo-and olanzapine-controlled Study. Am J Psychiatry 2011;168:957-67
3. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, doubleblind, placebo-and active-controlled trial. Schizophr Res 2013;145:101-9
4. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved secondgeneration antipsychotic. Int J Clin Pract 2011;65:189-210
5. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012;27:165-76
6. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013;147:95-102
7. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebocontrolled study. Am J Psychiatry 2014;171:161-8
8. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:2
9. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81
10. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572:160-70
11. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB. Effects of lurasidone in behavior models of depression. Role of the 5-HT receptor subtype. Neuropharmacology 2013;70C:211-17
12. Tarazi FI, Riva MA. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin Drug Discov 2013;8(10):1297-307
13. Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Ann Pharmacother 2012;46(7-8):1033-46
14. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-26
15. Flower R, Rang HP, Dale MM, et al. Rang & Dale's pharmacology. Edinburgh; Churchill Livingstone: 2007; ISBN 0-443-06911-5
16. DA. Drug Interactions: cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. 2007. Available from: http://medicine. iupui.edu/clinpharm/ddis/table.asp
17. FASS. Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta for forskrivare). http://www.fass.se/LIF/healthcarefacts? userType=0 Retrieved July 2014
18. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:829-36
19. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
20. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
21. Lloyd LC, Giaroli G, Taylor D, Tracy DK. Bipolar depression: clinically missed, pharmacologically mismanaged. Ther Adv Psychopharmacol 2011;1(5):153-62
22. Michalak EE, Murray G, Young AH, Lam RW. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs 2008;22(5):389-406
23. Nierenberg AA, Ostergaard SD, Iovieno N, et al. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol 2014; Epub ahead of print
24. Keck PE Jr, Welge JA, McElroy SL, et al. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry 2000;47(8):748-55
25. Van der Loos ML, Mulder PG, Hartong EG, et al. for the LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-31
26. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004;19(6):369-86
27. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat 2012;8:155-68
28. Crum C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and Mortality in Bipolar Disorder: a Swedish National Cohort Study. JAMA Psychiatry 2013;70(9):931-9
29. Radaelli D, Poletti S, Gorni I, et al. Neural correlates of delusion in bipolar depression. Psychiatry Res 2014;221(1):1-5
30. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014;47:199-211
31. Andreazza AC, Kauer-Sant'Anna M, Frey BN, et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 2008;33:516-24
32. Khairova R, Pawar R, Salvadore G, et al. Gattaz, Machado-Vieira R: WF, Effects lithium oxidative stress parameters healthy subjects. Mol Med Rep 2012;5(3):680-2
33. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33-6
34. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523-9
35. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005;58:879-84
36. Bachmann R, Wang Y, Yuan P, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009;12(6):805-22
37. Carta MG, Sorbello O, Moro MF, et al. Bipolar disorders and Wilson's disease. BMC Psychiatry 2012;12(1):52
38. Carta MG, Moro MF, Lorefice L, et al. The risk of Bipolar Disorders in Multiple Sclerosis. J Affect Disord 2014;155:255-60
39. Carta MG, Moro MF, Lorefice L, et al. Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life. J Affect Disord 2014;167C:192-7
40. Mura G, Bhat KM, Pisano A, et al. Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Health 2012;8:30-5
41. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010;167:1305-20
42. Liu X, Zhang T, He S, et al. Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res 2014;218(1-2):54-60
43. Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct 2012;8(1):61
44. Omata N, Mizuno T, Mitsuya H, Wada Y. Multiaxial evaluation of the pathophysiology of mood disorder and therapeutic mechanisms of clinical drugs by neuronal plasticity and neuronal load. Nihon Shinkei Seishin Yakurigaku Zasshi 2013;33(5-6):231-6
45. Hardoy MC, Garofalo A, Carpiniello B, et al. Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clin Pract Epidemol Ment Health 2005;1:7
46. Hardoy MC, Carta MG. Strategy to accelerate or augment the antidepressant response and for an early onset of ssri activity. adjunctive amisulpride to fluvoxamine in major depressive disorder. Clin Pract Epidemiol Ment Health 2010;6:1-3
47. Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013;149(1-3):196-201
48. Moro MF, Carta MG. Evaluating aripiprazole as a potential bipolar disorder therapy for adults. Expert Opin Investig Drugs 2014;1-18; Epub ahead of print
49. Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 2002;7(3):247-53
50. Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205(1):119-28
51. Delille HK, Becker JM, Burkhardt S, et al. Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 2012;62:2184-91
52. Luoni A, Hulsken S, Cazzaniga G, et al. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmcol 2012;20:1-12
53. Yuen EY, Li X, Wei J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Mol Pharmacol 2012;81:113-19
54. Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J Neurosci 2008;28:11760-7
55. Guzowski JF, Lyford GL, Stevenson GD, et al. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-termpotentiation and the consolidation of long-termmemory. J Neurosci 2000;20:3993-4001
56. Roberts AJ, Hedlund PB. The 5-HT(7) receptor in learning and memory. Hippocampus 2012;22:762-71
57. Wesolowska A, Tatarczynska E, Nikiforuk A, Chojnacka-Wojcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007;555:43-7
58. Fumagalli F, Calabrese F, Luoni A, et al. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 2012;15:235-46
59. Peters J, Dieppa-Perea LM, Melendez LM, Quirk GJ. Induction of fear extinction with hippocampalinfralimbic BDNF. Science 2010;328:1288-90
60. Calabrese F, Luoni A, Guidotti G, et al. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology (Berl) 2013;226(1):101-12
61. Gavin DP, Sharma RP, Chase KA, et al. Growth arrest and DNAdamageinducible, beta (GADD45b)-mediated DNA demethylation in major psychosis. Neuropsychopharmacology 2012;37:531-42
62. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 2013;9:1521-9
63. Kozicky JM, Torres IJ, Silveira LE, et al. Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. J Clin Psychiatry 2014;75(6):e587-93
64. Goodwin GM. and; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23(4):346-88
65. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014;28(5):421-53
66. Chan H, Lin AS, Chen KP, et al. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. J Clin Psychopharmacol 2013;33(6):747-52
67. Rabkin SW. Aging effects on QT interval: implications for cardiac safety of antipsychotic drugs. J Geriatr Cardiol 2014;11(1):20-5
68. Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013;11:CD006625
69. Suzuki Y, Watanabe J, Sugai T, et al. Improvement in QTc prolongation induced by zotepine following a switch to perospirone. Psychiatry Clin Neurosci 2012;66(3):244